ArticleArchives of medical science : AMS2023
Long non-coding RNA GASL1 inhibits proliferation and invasion of osteosarcoma cells via modulation of the PI3K/Akt pathway.
Article in Archives of medical science : AMS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Novel insights into lncRNAs as key regulators of post-translational modifications in cancer: mechanisms and therapeutic potential.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- lncRNA GAPLINC regulates vascular endothelial cell apoptosis in atherosclerosis.Archives of medical science : AMS · 2024Article
- Interaction of ncRNAs and the PI3K/AKT/mTOR pathway: Implications for osteosarcoma.Open life sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Studies have shown long non-coding RNAs to be involved in a wide array of cancer-related processes. This study analyzed the role of LncRNA GAL1 in osteosarcoma cancer proliferation, migration and invasion of cancer cells. Material and methods: The qRT-PCR technique was used to determine the expression of GASL1. MTT assay was performed for analysis of cell viability. Migration of cancer cells was monitored by wound healing assay. Transwell assay was used for analysis of cancer cell invasion. Western blotting was performed for determination of protein expression levels. Results: The results showed that GASL1 exhibits lower expression in osteosarcoma tissues and cell lines than normal surroundings tissues and osteoblasts respectively. GASL1 overexpression resulted in a decline of cancer cell viability as revealed by MTT and colony formation assays. The migration and invasion of cancer cells decreased remarkably when GASL1 was overexpressed in cancer cells. GASL1 over-expression also affected the Bax/Bcl-2 ratio and promoted cell apoptosis. The anticancer effects of GASL1 overexpression were found to be mediated via the PI3K/Akt signaling pathway. GASL1 was seen to play an inhibitory role in PI3K and Akt phosphorylation. Conclusions: Long ncRNA GASL1 inhibits the growth of osteosarcoma cancer cells. Cell apoptosis was promoted via inactivation of the PI3K/Akt signaling pathway. Taken together LncRNA GAL1 may prove to be a beneficial therapeutic target in the treatment of osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.